Item
1.01
|
Entry
into a Material Definitive Agreement.
|
Underwriting
Agreement
On April 4, 2019, InspireMD,
Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright
& Co., LLC (the “Underwriter”), relating to an underwritten public offering of 486,957 shares (the “Shares”)
of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). All of the Shares are being
sold by the Company. The offering price to the public of the Shares is $5.00 per share, and the Underwriter has agreed
to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $4.65 per share. Under the terms
of the Underwriting Agreement, the Company granted the Underwriter an option (the “Underwriter Option”), exercisable
for 30 days, to purchase up to an additional 73,043 shares of Common Stock at the same price per share as the Shares. After underwriting
discounts and commissions, the Company expects to receive gross proceeds from the offering, before deducting underwriting discounts
and commissions and other offering expenses payable by the Company, of $2.4 million.
Pursuant to the Underwriting
Agreement, the Company, in connection with the offering, agreed to issue to the Underwriter warrants to purchase 34,087 shares
of Common Stock, or, if the Underwriter exercises the Underwriter Option, up to an additional 5,113 shares of
Common Stock, representing 7% of the number of shares of Common Stock sold in the offering (the “Underwriter Warrants”
and together with the shares issuable upon exercise of the Underwriter Warrants, the “Underwriter Securities”). The
Underwriter Warrants will be exercisable at any time and from time to time, in whole or in part, following the date of issuance
and ending five years from the date of the execution of the Underwriting Agreement, at a price per share equal to $6.25 (125%
of the offering price to the public per Share).
The Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (Registration
Statement No. 333-223130) previously filed with the Securities and Exchange Commission (the “Commission”) and declared
effective by the Commission on February 23, 2018. A preliminary prospectus supplement and the accompanying prospectus relating
to the offering have been filed with the Commission. The offering is expected to close on or about April 8, 2019, subject to satisfaction
of customary closing conditions.
A
copy of the legal opinion and consent of Haynes and Boone, LLP relating to the validity of the issuance and sale of the Shares
is attached as Exhibit 5.1 hereto.
The Underwriting Agreement contains customary representations and warranties, agreements and obligations,
conditions to closing and termination provisions. The Underwriting Agreement provides for indemnification by the Underwriter of
the Company, its directors and certain of its executive officers, and by the Company of the Underwriter, for certain liabilities,
including liabilities arising under the Securities Act of 1933, as amended, and affords certain rights of contribution with respect
thereto.
Subject to certain exceptions,
the Company, its executive officers, directors and certain shareholders have agreed not to sell or transfer any shares of Common
Stock or securities convertible into or exchangeable or exercisable for shares of Common Stock, for 90 days after April
4, 2019 without first obtaining the written consent of the Underwriter. The Company has also agreed not to enter into or effect
a “variable rate transaction” for a period of 12 months from the closing of the offering without the prior written
consent of the Underwriter (which may be withheld in its sole discretion), subject to certain limited exceptions.
The
foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which
is attached as Exhibit 1.1 hereto and incorporated by reference herein.